ArticleMedicine2026
Causal effects between blood metabolites and myocardial infarction: A 2-sample Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Observational studies have reported associations between circulating blood metabolite features and myocardial infarction (MI), but whether these associations are causal remains uncertain. Mendelian randomization (MR) can strengthen causal inference by using genetic variants as instrumental variables. We therefore conducted a 2-sample MR study, followed by pathway enrichment analysis, to evaluate the potential causal effects of genetically predicted blood metabolite features on MI. Genetic association data for 452 blood metabolite features were obtained from a published metabolomics GWAS including 7824 participants of European ancestry. The metabolite panel comprised annotated small molecules and lipids as well as a limited number of peptide/partially annotated or unknown metabolite signatures defined in the source GWAS. Summary statistics for MI were obtained from FinnGen (n = 369,139) and the IEU Open GWAS project (n = 461,823), and a discovery-replication design was applied. The inverse-variance weighted method was the primary MR analysis, complemented by weighted median, MR-Egger, weighted mode, and simple mode. Sensitivity analyses included Cochran Q test, MR-Egger intercept, funnel plots, and leave-one-out analyses. Significant findings were further evaluated using pathway enrichment analysis. In FinnGen, 12 annotated metabolite features were associated with a lower MI risk, and 8 annotated metabolite features were associated with a higher MI risk after excluding unknown signatures from the descriptive summary. In the IEU Open GWAS dataset, 10 annotated metabolite features were protective, and 7 were risk-associated. Glycine, N-acetylglycine, deoxycholate, propionylcarnitine, and margarate (17:0) showed directionally consistent associations across both MI datasets, supporting the robustness of these findings. This 2-sample MR analysis supports potential causal roles of several circulating metabolite features in MI. These findings expand the evidence base for metabolic mechanisms underlying MI and may help prioritize biomarkers and pathways for future validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.